GLP-1 & Incretin Science

Why a Safety Report Count Climbs

UKPWritten and published by UK Peptides4 min readUpdated 3 cited sources

The short answer

A rising count of adverse event reports for a newly marketed drug is expected and largely uninformative about risk. Exposure grows, awareness grows, and reporting itself follows a well-documented curve that peaks a few years after launch and then declines.

Key facts

Observation
Tirzepatide ketoacidosis reports in non-diabetics
2022 rate
1-2 cases per quarter
2025 rate
28-34 cases per quarter
Tirzepatide US approval
May 2022 (type 2 diabetes)
Semaglutide US approvals
2017 (diabetes), 2021 (weight management)
What is missing
Number of people exposed in each quarter
Named effect
Weber effect / notoriety bias
Correct interpretation
A prompt for a denominator-based study

The observation, and why it looks alarming

Makhmutov and Qureshi analysed FAERS reports from January 2021 to December 2025 and found that ketoacidosis reports for tirzepatide in non-diabetic patients rose from one or two per quarter in 2022 to 28 to 34 per quarter by 2025, a fifteen- to thirty-fold increase over three years. Written as a headline, that reads as an escalating safety problem. Written with its denominator it reads as nothing much at all, and the denominator is what a spontaneous reporting system does not have.

Exposure is the first and largest explanation

Tirzepatide was first approved in the United States in May 2022. In the first quarter of that curve there were almost no people taking it. By 2025 there were millions. If the per-person risk were exactly constant, the raw count would still have risen by something close to the same factor as the prescription volume. A count that grows in step with uptake carries no information about whether the drug became more dangerous, and separating the two requires a denominator that FAERS cannot supply.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Reporting behaviour has its own curve

Beyond exposure, reporting rates for a given drug are not stable over time. The pattern usually called the Weber effect describes reporting for a newly marketed drug rising for roughly the first two years and then declining, independent of any change in the underlying risk. Layered on top is notoriety bias: once an association is discussed in the literature or the press, clinicians who see the event start attributing it to the drug and reporting it, which increases counts for a reason that is entirely about attention. A drug approved in 2022 and a drug approved in 2017 sit at different points on both curves at any given moment, which is one of the strongest reasons not to compare their raw counts.

What the same paper's controlled comparison shows

The disproportionality analysis in that paper is the part that carries information, because it normalises against the rest of the database. Semaglutide showed a ketoacidosis reporting odds ratio of 3.15 (95% CI 2.78 to 3.56); tirzepatide showed 1.22 (95% CI 1.06 to 1.39). Both are above one and both are statistically distinguishable from it, so both drugs have a signal. But the drug whose raw count was climbing fastest has the smaller ratio, which is what you would expect if the climbing count were mostly uptake. The trend line and the ratio point in opposite directions, and only one of them is adjusted for anything.

Where the counts do carry information

Two places. The proportion of reported cases that were serious is not affected by the missing denominator in the same way, because it is a ratio within the reported cases: hospitalisation was required in 74.3% of semaglutide cases and 71.3% of tirzepatide cases in that analysis, which says something real about the severity of the cases that do get reported, whatever their frequency. And an abrupt discontinuity (counts jumping in a period when exposure did not) is a real signal, because the usual explanations do not fit. A smooth rise tracking a product launch is not that.

The general rule

Any raw adverse event count for a recently launched drug should be read as a measure of how much the drug is being used and discussed, with a risk signal somewhere inside it that the count alone cannot isolate. The way to isolate it is a study with people in the denominator: a cohort, a case-control design, a self-controlled case series, or a health-record analysis where exposure time is measured. Those studies are slower, which is why the fast, biased number is the one that circulates first.

Frequently asked questions

Is euglycaemic ketoacidosis a real concern with these drugs?

Both agents showed statistically significant disproportionality signals in the analysis described here, and the reported cases were frequently serious. That is a reason for the question to be studied properly, which is what a signal is for. It is not, by itself, a measurement of how often it happens.

Why not just divide the reports by prescriptions?

People do try, and the result is called a reporting rate. It is better than nothing but still unreliable, because the fraction of true events that get reported is unknown, varies by drug, by country, by seriousness and over time. Dividing an unknown fraction by a known denominator does not produce a rate.

Does the Weber effect always hold?

It is a described pattern, not a law, and studies since the original description have found it holds for some drugs and periods and not others, particularly where a drug's use expands sharply years after launch, as has happened across this class. It is a reason for caution about time trends rather than a correction that can be applied.

How long before real risk estimates arrive?

For a drug launched in 2022, cohort studies with adequate follow-up begin appearing around three to five years later. That gap is exactly the period in which spontaneous report counts are least interpretable and most quoted.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.